FIELD: medicine, pharmaceutics.
SUBSTANCE: pharmaceutical composition by invention possesses antagonistic activity with respect to angiotensin II. Pharmaceutical composition contains 30-80 wt % of inrbesartan or its pharmaceutically acceptable salt as active ingredient and more than 10 wt % of loosening agent in terms of complete composition weight. Pharmaceutical composition does not contain silicon-containing antiadhesive. Pharmaceutical composition of irbesartan is made in form of tablet with film coating. Also described is method of irbesartan tablet manufacturing.
EFFECT: irbesartan tablet possesses dissolution profile at which 80 wt % or more of irbesartan dissolve not later than after 30 min.
25 cl, 1 dwg, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITIONS CONTAINING PRODRUG OF HCV POLYMERASE INHIBITOR | 2010 |
|
RU2489153C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING DGAT1 INHIBITOR | 2011 |
|
RU2595866C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING TYPE 2 DIABETES | 2010 |
|
RU2533560C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING ALEGLITEZAR | 2010 |
|
RU2537224C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING N-[3-CHLOR-4-[(3-FLUOROPHENYL)METHOXY]PHENYL]-6-[5[[[2-(METHYLSULPHONYL)ETHYL]AMINO]METHYL]-2-FURYL]-4-QUINAZOLINAMINE | 2009 |
|
RU2548757C2 |
| NEW COMPOSITION OF LAPATINIB AS A SOLID DOSAGE FORM FOR ORAL USE AND A METHOD OF ITS MANUFACTURE | 2019 |
|
RU2821950C2 |
| ORAL SOLID DOSAGE FORM AND METHOD OF TREATING | 2011 |
|
RU2480210C1 |
| HALENIC COMPOSITIONS OF ORGANIC COMPOUNDS | 2005 |
|
RU2384328C2 |
| IRBESARTAN-CONTAINING PHARMACEUTICAL COMPOSITIONS | 1996 |
|
RU2210368C1 |
| PREPARATION OF GLUCOKINASE ACTIVATOR FOR ORAL ADMINISTRATION AND METHOD FOR PREPARATION THEREOF | 2017 |
|
RU2728824C1 |
